ATE76412T1 - HOMOGENEOUS ERYTHROPOIETIN. - Google Patents

HOMOGENEOUS ERYTHROPOIETIN.

Info

Publication number
ATE76412T1
ATE76412T1 AT86900400T AT86900400T ATE76412T1 AT E76412 T1 ATE76412 T1 AT E76412T1 AT 86900400 T AT86900400 T AT 86900400T AT 86900400 T AT86900400 T AT 86900400T AT E76412 T1 ATE76412 T1 AT E76412T1
Authority
AT
Austria
Prior art keywords
erythropoietin
homogeneous
reverse phase
purifying
homogeneous erythropoietin
Prior art date
Application number
AT86900400T
Other languages
German (de)
Inventor
Rodney M Hewick
Jasbir S Seehra
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24774236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE76412(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst filed Critical Genetics Inst
Application granted granted Critical
Publication of ATE76412T1 publication Critical patent/ATE76412T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/834—Urine; urinary system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/30—Signal or leader sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method for purifying erythropoietin is described. The method comprises treating partially purifying erythropoietin by reverse phase high performance liquid chromatography to obtain homogeneous erythropoietin having a molecular weight of about 34,000 daltons on SDS PAGE and moving a single peak on reverse phase HPLC. The homogeneous erythropoietin protein preferably has a specific activity of at least 120,000 IU, more preferably at least 160,000 IU per absorbance unit at 280 nm.
AT86900400T 1985-01-11 1985-11-27 HOMOGENEOUS ERYTHROPOIETIN. ATE76412T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/690,853 US4677195A (en) 1985-01-11 1985-01-11 Method for the purification of erythropoietin and erythropoietin compositions
PCT/US1985/002358 WO1986004068A1 (en) 1985-01-11 1985-11-27 Homogeneous erythropoietin
EP86900400A EP0209539B1 (en) 1985-01-11 1985-11-27 Homogeneous erythropoietin

Publications (1)

Publication Number Publication Date
ATE76412T1 true ATE76412T1 (en) 1992-06-15

Family

ID=24774236

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86900400T ATE76412T1 (en) 1985-01-11 1985-11-27 HOMOGENEOUS ERYTHROPOIETIN.

Country Status (11)

Country Link
US (1) US4677195A (en)
EP (1) EP0209539B1 (en)
JP (1) JPS62501701A (en)
AT (1) ATE76412T1 (en)
AU (1) AU584032B2 (en)
BR (1) BR1100044A (en)
DE (1) DE3586104D1 (en)
HK (1) HK105793A (en)
MX (1) MX9203128A (en)
SG (1) SG93893G (en)
WO (1) WO1986004068A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900811A (en) * 1983-07-21 1990-02-13 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
US5242798A (en) * 1983-07-21 1993-09-07 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
KR850004274A (en) * 1983-12-13 1985-07-11 원본미기재 Method for preparing erythropoietin
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
UA29377C2 (en) * 1984-09-19 2000-11-15 Новартіс Аг Method for preparing protein with activity of granulocyte macrophage-colony stimulating factor (gm-csf) of primates
US5322837A (en) * 1985-01-11 1994-06-21 Genetics Institute, Inc. Homogeneous erythropoietin compositions and methods of using same
IL79176A (en) * 1985-06-20 1992-06-21 Kirin Amgen Inc Process for the recovery of erythropoietin from a fluid
DE3686582T2 (en) * 1985-11-27 1993-01-28 Genetics Inst TREATING AN AIDS TYPE DISEASE.
ES2065318T3 (en) * 1986-07-15 1995-02-16 Kowa Co SUBSTANCE THAT JOINS THROMBIN AND PROCEDURE FOR ITS PREPARATION.
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US4965251A (en) * 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
DE3924746A1 (en) * 1989-07-26 1991-01-31 Behringwerke Ag ERTHROPOIETIN (EPO) PEPTIDES AND ANTIBODIES THEREFOR
US6932968B1 (en) 1989-07-26 2005-08-23 Dade Behring Marburg Gmbh Erythropoietin (EPO) peptides and antibodies directed against these
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
IL117849A (en) * 1995-04-14 2002-07-25 Lepetit Spa Chromatographic process for the purification of glycoproteins
IL118201A (en) * 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
US5981716A (en) * 1995-06-07 1999-11-09 Gruppo Lepettit, S.P.A. Process for the purification of proteins
EP0752474A1 (en) 1995-07-07 1997-01-08 Boehringer Mannheim Gmbh Nucleic acid coding for CMP-N-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
KR100400637B1 (en) * 1996-02-06 2004-03-10 씨제이 주식회사 Biologically useful peptide
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US6004808A (en) * 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
US5985214A (en) 1997-05-16 1999-11-16 Aurora Biosciences Corporation Systems and methods for rapidly identifying useful chemicals in liquid samples
WO1999054486A1 (en) * 1998-04-22 1999-10-28 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
US6696411B1 (en) * 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
BR9905868A (en) * 1998-11-06 2001-01-23 Bio Sidus S A Mass culture procedure for mammalian cells to obtain recombinant human erythropoietin and recombinant human erythropoietin obtained with such procedure
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
US6703480B1 (en) * 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSED PROTEINS
CA2431964C (en) 2000-12-20 2013-09-10 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
PE20021017A1 (en) * 2001-04-03 2002-11-24 Pharmacia Corp RECONSTITUABLE PARENTERAL COMPOSITION
CN1596268A (en) * 2001-11-28 2005-03-16 桑多斯有限公司 Chromatographic purification of recombinant human erythropoietin
PT1463751E (en) 2001-12-21 2013-08-26 Human Genome Sciences Inc ALBUMINE FUSION PROTEINS
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
JP2007500218A (en) * 2003-05-12 2007-01-11 アフィーマックス・インコーポレイテッド New spacer moiety of poly (ethylene glycol) modified peptide compounds
DE602004020610D1 (en) * 2003-05-12 2009-05-28 Affymax Inc NEW PEPTIDE BINDING TO THE ERYTHROPOIETIN RECEPTOR
EP1626983B8 (en) * 2003-05-12 2010-12-22 Affymax, Inc. Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
ES2395413T3 (en) * 2003-05-12 2013-02-12 Affymax, Inc. Peptides that bind to the erythropoietin receptor
DK1699915T3 (en) 2003-12-30 2010-09-13 Augustinus Bader Use of erythropoietin for liver tissue regeneration
WO2006060148A2 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) * 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP1978030A4 (en) 2006-01-18 2009-12-30 Chugai Pharmaceutical Co Ltd SIALIC ACID REMOVAL METHOD AND METHOD FOR PRODUCING ASIALOERYTHROPOIETIN
EP1997505A4 (en) * 2006-03-22 2013-02-13 Chugai Pharmaceutical Co Ltd PREPARATION OF ERYTHROPOIETIN SOLUTION
AU2007255717B2 (en) 2006-06-07 2013-07-11 Chugai Seiyaku Kabushiki Kaisha Treatment of ischemic disease using erythropoietin
WO2008019214A1 (en) 2006-08-04 2008-02-14 Prolong Pharmaceuticals, Inc. Modified erythropoietin
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
DE102008002210A1 (en) 2008-06-04 2009-12-10 Evonik Degussa Gmbh Process for the fermentative production of erythropoietin
EP2334699B1 (en) 2008-09-23 2013-09-11 F. Hoffmann-La Roche AG Purification of erythropoietin
EA022396B1 (en) * 2009-09-23 2015-12-30 Ратиофарм Гмбх Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
WO2012097256A1 (en) 2011-01-14 2012-07-19 University Of Tennessee Research Foundation Therapeutic compositions and methods for disorders associated with neuronal degeneration
EP2970420A4 (en) 2013-03-15 2016-08-17 Apotex Inc Enhanced liquid formulation stability of erythropoietin alpha through purification processing
JP6920280B2 (en) * 2016-03-31 2021-08-18 株式会社カネカ Method for Producing Purified Cat-Derived Erythropoietin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3033753A (en) * 1959-08-31 1962-05-08 Wilfrid F White Erythropoietic factor purification
US4254095A (en) * 1978-04-27 1981-03-03 Research Corporation Radioimmunoassay for erythropoietin
US4377482A (en) * 1978-04-28 1983-03-22 Salk Institute For Biological Studies Mobile phase for liquid chromatography
IN150740B (en) * 1978-11-24 1982-12-04 Hoffmann La Roche
JPS5653696A (en) * 1979-10-09 1981-05-13 Ajinomoto Co Inc Isolation of erythropoietin by adsorption
JPS6045849B2 (en) * 1980-08-25 1985-10-12 林原 健 Method for producing human erythropoietin
JPS57149228A (en) * 1981-03-11 1982-09-14 Ajinomoto Co Inc Novel erythropoietin and its preparation
US4558005A (en) * 1982-09-13 1985-12-10 University Patents, Inc. Monoclonal anti-erythropoietin
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
JPH0686480B2 (en) * 1983-02-21 1994-11-02 雪印乳業株式会社 Monoclonal antibody for erythropoietin production
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IT1185503B (en) * 1984-01-11 1987-11-12 Univ New York HUMAN Erythropietine ODNA CLONES
US4568488A (en) * 1984-01-11 1986-02-04 Lee Huang Sylvia Reverse immunoaffinity chromatography purification method
IL77081A (en) * 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin

Also Published As

Publication number Publication date
JPS62501701A (en) 1987-07-09
DE3586104D1 (en) 1992-06-25
AU584032B2 (en) 1989-05-11
EP0209539B1 (en) 1992-05-20
SG93893G (en) 1994-02-25
EP0209539A1 (en) 1987-01-28
US4677195A (en) 1987-06-30
MX9203128A (en) 1992-07-01
JPH0138800B2 (en) 1989-08-16
HK105793A (en) 1993-10-15
BR1100044A (en) 2000-02-08
EP0209539A4 (en) 1988-07-29
WO1986004068A1 (en) 1986-07-17
AU5191186A (en) 1986-07-29

Similar Documents

Publication Publication Date Title
MX9203128A (en) Homogeneous erythropoietin.
BR8602294A (en) PERFECT CATALYTIC PROCESS TO PRODUCE 1,4-CISPOLIBUTADIENO OR BUTADIEN COPOLIMER
FI882890A7 (en) A molecule with coagulation activity similar to factor VIII:C.
ATE195124T1 (en) CONDENSED PYRROLO(2,3-C) CARBAZOLE-6-ONE WHICH POTENTIATE THE ACTIVITY OF GAMMA INTERFERON
FI861424A7 (en) An improved method for conjugating metallothionein to biologically active molecules.
SE8005498L (en) HOMOGENT FIBROBLAST INTERFERENCE AND PREPARATION OF IT
FI870663A7 (en) FETTEMULSIONER, SOM INNEHAOLLER PROSTAGLANDIN I 2.
DE3768215D1 (en) CIS-TRANS ISOMERIZATION OF 1,4-DIHALOBUTEN-2.
DE3676973D1 (en) CONTROLLED, TOPICAL APPLICATION OF ACTIVE SUBSTANCES.
EP0373540A3 (en) Method for purifying fibroblast growth factor protein
DE3584059D1 (en) AMID DERIVATIVES WITH BIOLOGICAL EFFECT.
BR8907015A (en) PROCESS TO PRODUCE 2,6-DIETHYLNAPHTHALENE
NO863562L (en) ACCESSORIES FOR WHEELCHAIRS, PRIOR TO CARS.
ES2065318T3 (en) SUBSTANCE THAT JOINS THROMBIN AND PROCEDURE FOR ITS PREPARATION.
DK155463C (en) STAINLESS STEEL BOAT, ISAIR FOR WOOD
DK10190A (en) 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES
FI875397A7 (en) Substituted aminomethyl-5,6,7,8 -tetrahydronaphthyloxyacetic acids, new intermediates, a method for their preparation and their use in pharmaceuticals.
MX9207468A (en) PROCESS TO PREPARE PURIFIED 2,6-NAFTALENODICARBOXILICO ACID.
FI895874A7 (en) Dipeptide derivatives with enzyme-inhibiting activity
IT8619456A0 (en) PROSTAGLANDIN ANALOGUES REPLACED WITH TIABICICLOEPTANE AVENYI CARDIOVASCULAR ACTIVITY.
KR890017268A (en) Proteins with Antitumor Activity
FI861951A7 (en) 1,3-OXATHIENE DERIVATIVES.
FI891121A7 (en) Method for purifying factor XIII by affinity chromatography
ES546136A0 (en) PROCESS TO PRODUCE DERIVATIVES OF 1,4-DIHIDRO-PIRIDINA-3,5, DICARBOXILATO.
NO860469L (en) Distillation column.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee
RZN Patent revoked